Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.43 |
| ▸ | CASP2 | P42575 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24611784 | 0.91 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MEN1KMT2APAOX | |
| SCHEMBL14198854 | 0.91 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2MEN1KMT2APAOX | |
| SCHEMBL28969880 | 0.88 | CA1 (0.39) | ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL16853212 | 0.88 | ALDH1A1 (0.55) | ALDH1A1SMN1; SMN2MEN1KMT2APAOX | |
| Hydrochloric Acid SCHEMBL25330006 | 0.86 | CA1 (0.38) | ALDH1A1MEN1KMT2AAOC3 | |
| SCHEMBL10276927 | 0.84 | PAOX (0.61) | ALDH1A1SMN1; SMN2MEN1KMT2APAOX | |
| SCHEMBL19186288 | 0.84 | PAOX (0.61) | ALDH1A1SMN1; SMN2MEN1KMT2APAOX | |
| SCHEMBL12660515 | 0.83 | MEN1 (0.48) | ALDH1A1SMN1; SMN2MEN1KMT2APAOX | |
| SCHEMBL7436387 | 0.83 | PRMT1 (0.63) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPK1 | |
| SCHEMBL8519057 | 0.83 | PRMT1 (0.63) | ALDH1A1SMN1; SMN2MEN1KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288606-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-3858385-B1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. (US) | 2023-06-01 | — | — | US | disclosed |
| CN-107141410-B | Polymer-conjugated MetAP2 inhibitors and methods of treatment using the same | 辛德弗雷克斯公司 | 2022-12-09 | — | — | CN | disclosed |
| CN-107158398-B | Polymer-conjugated MetAP2 inhibitors and methods of treatment using the same | 辛德弗雷克斯公司 | 2022-02-18 | — | — | CN | disclosed |
| EP-3858385-A2 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | Syndevrx, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2021-05-06 | — | — | US | disclosed |
| EP-2576638-B1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX INC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10722532-B2 | Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190151353-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2019-05-23 | — | — | US | disclosed |
| US-20160256483-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2016-09-08 | — | — | US | disclosed |
| US-20160184345-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | SYNDEVRX, INC. | 2016-06-30 | — | — | US | disclosed |
| US-9320805-B2 | Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof | SYNDEVRX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2015-05-21 | — | — | US | disclosed |
| WO-2014169026-A1 | METAP2 INHIBITORS AND METHODS OF TREATING OBESITY | SYNDEVRX, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| US-20130216494-A1 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof | SynDecRx, Inc. (US) | 2013-08-22 | — | — | US | disclosed |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | SYNDEVRX, INC. | 2013-05-30 | — | — | US | disclosed |
| EP-2575887-A1 | OPTIMIZED DRUG CONJUGATES | Syndevrx (US) | 2013-04-10 | — | — | EP | disclosed |
| US-20110294952-A1 | Optimized Drug Conjugates | SynDevRX (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011150088-A1 | OPTIMIZED DRUG CONJUGATES | SynDevRX (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184345-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
| US-20110294952-A1 | Optimized Drug Conjugates | ABCB1, ABCG2, UGT1A3 | ALDH1A1 435/4885SMN1; SMN2 2416/4885MEN1 1471/4885 |
| US-20130216494-A1 | Polymer-Conjugated MetAP2 inhibitors, and Therapeutic Methods of Use Thereof | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
| US-20150141580-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | ALDH1A1 435/4885SMN1; SMN2 2416/4885MEN1 1471/4885 |
| US-10722532-B2 | Polymer-conjugated METAP2 inhibitors, and therapeutic methods of use thereof | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
| US-20230165892-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
| US-20190151353-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
| US-20250288606-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
| US-20210128607-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
| US-20130137831-A1 | OPTIMIZED DRUG CONJUGATES | ABCB1, ABCG2, UGT1A3 | ALDH1A1 435/4885SMN1; SMN2 2416/4885MEN1 1471/4885 |
| US-20160256483-A1 | POLYMER-CONJUGATED METAP2 INHIBITORS, AND THERAPEUTIC METHODS OF USE THEREOF | METAP2, MTX2, METAP1 | ALDH1A1 4179/4885SMN1; SMN2 741/4885MEN1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.